Advertisement

Scheduling synthetic cathinone substances under the Controlled Substances Act

  • Katherine R. BonsonEmail author
  • Tyler Dalton
  • Dominic Chiapperino
Review
  • 72 Downloads

Abstract

Background and rationale

Cathinones are amphetamine analogues that produce stimulant effects with rewarding properties. For many decades, synthetic cathinones have been used in the United States (USA) for abuse purposes, leading to concern about public safety by the federal government. Under the Controlled Substances Act (CSA), the federal government may place drugs with high abuse potential but no currently accepted medical use into Schedule I of the CSA. The process of scheduling an abusable drug involves both the Department of Health and Human Services (HHS), through the Food and Drug Administration (FDA) and the National Institute on Drug Abuse (NIDA), and the Department of Justice, through the Drug Enforcement Administration (DEA).

Results

This paper details how numerous synthetic cathinones were placed under CSA control between 1973 and 2018, with an emphasis on 10 cathinones that were placed into Schedule I in 2017 (butylone, naphyrone, pentylone, pentedrone, 3-fluoro-N-methylcathinone (FMC), 4-FMC, 4-methyl-N-ethylcathinone, 4-methyl-pyrrolidinopropiophenone, alpha-pyrrolidinobutiophenone, and α-pyrrolidinopentiophenone). A summary is provided of the scientific and medical analysis performed by HHS, in the form of an Eight-Factor Analysis (8FA), as prescribed by the CSA. This 8FA was then evaluated and signed by the Assistant Secretary for Health at HHS and transmitted to DEA, which permanently placed the 10 cathinones into Schedule I after public notices were published into the Federal Register.

Discussion and conclusions

Understanding the scientific data, analysis, and complex process utilized by the US federal government in the CSA scheduling of cathinones with abuse potential and no accepted medical use is important for transparency in governmental decision-making.

Keywords

Cathinone Scheduling Abuse Regulation Food and Drug Administration (FDA) Department of Health and Human Services (HHS) Drug Enforcement Administration (DEA) Controlled Substances Act (CSA) Psychotropic convention 

Notes

Acknowledgements

The authors thank James Hunter of the Controlled Substance Staff at the Food and Drug Administration for expertise on international drug scheduling issues.

Compliance with ethical standards

Conflict of interest statement

The authors declare that they have no conflict of interest.

Disclaimer

This paper reflects the views of the authors and does not necessarily represent those of FDA.

References

  1. Drug Enforcement Administration/Department of Justice, (2014) Data Review Document: Eight Factor Analysis for 4-methyl-N-ethylcathinone (4-MEC), 4-methyl-pyrrolidino-propiophenone (4-MePPP), alpha-pyrrolidinopentiophenone (α-PVP), 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone), 2-(methylamino)-1-phenylpentan-1-one (pentedrone), 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone), 4-fluoro-N-methylcathinone (4-FMC; flephedrone), 3-fluoro-N-methylcathinone (3-FMC), 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone), alpha-pyrrolidinobutiophenone (α-PBP). Submitted to Dr. Karen DeSalvo, Acting Assistant Secretary for Health, Department of Health and Human ServicesGoogle Scholar
  2. AAPCC (2013) American Association of Poison Control Centers. Bath salts dataGoogle Scholar
  3. AAPCC (2014) American Association of Poison Control Centers. 2014. Bath salts dataGoogle Scholar
  4. Aarde SM, Creehan KM, Vandewater SA, Dickerson TJ, Taffe MA (2015) In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacology 232(16):3045–3055CrossRefGoogle Scholar
  5. Balster RL, Bigelow GE (2003) Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13–S40CrossRefGoogle Scholar
  6. Banks ML, Worst TJ, Rusyniak DE, Sprague JE (2014) Synthetic cathinones (“bath salts”). J Emerg Med 46(5):632–642CrossRefGoogle Scholar
  7. Doat MM, Rabin RA, Winter JC (2003) Characterization of the discriminative stimulus properties of centrally administered (−)-DOM and LSD. Pharmacol Biochem Behav 74(3):713–721CrossRefGoogle Scholar
  8. Derungs A, Schietzel S, Meyer MR, Maurer HH, Krähenbühl S, Liechti ME (2011) Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone). Clin Toxicol 49(7):691–693CrossRefGoogle Scholar
  9. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85(12):1803–1815CrossRefGoogle Scholar
  10. Forster MJ, Rutledge M, Gatch MB (2014) Discriminative and locomotor effects of three synthetic cathinones. College on Problems of Drug Dependence conference program 76:57Google Scholar
  11. Frohlich S, Lambe E, O’Dea J (2011) Acute liver failure following recreational use of psychotropic “head shop” compounds. Ir J Med Sci 180(1):263–264CrossRefGoogle Scholar
  12. Gatch MB, Dolan SB, Forster MJ (2015a) Comparative behavioral pharmacology of three pyrrolidine containing synthetic cathinone derivatives. J Pharmacol Exp Ther 354(2):103–110CrossRefGoogle Scholar
  13. Gatch MB, Rutledge MA, Forster MJ (2015b) Discriminative and locomotor effects of five synthetic cathinones in rats and mice. Psychopharmacology 232(7):1197–1205CrossRefGoogle Scholar
  14. Gatch MD, Taylor C, Forster MJ (2013) Locomotor stimulant and discriminative stimulus effects of “bath salt” cathinones. Behav Pharmacol 24:437–447CrossRefGoogle Scholar
  15. Hwang JY, Kim JS, Oh JH, Hong SI, Ma SX, Jung YH, Ko YH, Lee SY, Kim HC, Jang CO (2017) The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity. Addict Biol 22(1):117–128CrossRefGoogle Scholar
  16. Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL (2013) Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700(1–3):147–151CrossRefGoogle Scholar
  17. Kaizaki A, Tanaka S, Numazawa S (2014) New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. J Toxicol Sci 39(1):l–6Google Scholar
  18. Lehmann T, Geisshüsler S, Brenneisen R (1990) Rapid TLC identification test for khat (Catha edulis). Forensic Sci Int 45:47–51CrossRefGoogle Scholar
  19. Marusich JA, Grant KR, Blough BE, Wiley JL (2012) Effects of synthetic cathinones contained in “bath salts” on motor behavior and a functional observational battery in mice. Neurotoxicology 33(5):1305–1313CrossRefGoogle Scholar
  20. Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 87:206–213CrossRefGoogle Scholar
  21. Meltzer PC, Butler D, Deschamps JR, Madras BK (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-ylpentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49(4):1420–1432CrossRefGoogle Scholar
  22. National Institute on Drug Abuse (2011–2013). Report. Contracts. NOIDA-7-8872 and NOIDA-13-8908 or ADA 12012. Unpublished dataGoogle Scholar
  23. Naylor JE, Freeman KB, Blough BE, Woolverton WL, Huskinson SL (2015) Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats. Drug Alcohol Depend 149:280–284CrossRefGoogle Scholar
  24. Rojek S, Klys M, Strona M, Maciów M, Kula K (2012) “Legal highs”—toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration. Forensic Sci Int 222(1–3):el–e6Google Scholar
  25. Substance Abuse Mental Health Services Administration (2013) The DAWN Report. “Bath Salts” were involved in over 20,000 drug-related emergency department visits in 2011. http://www.samhsa.gov/data (accessed September 17, 2013)
  26. Sannerud CA, Ator NA (1995) Drug discrimination analysis of midazolam under a three-lever procedure: I. Dose-dependent differences in generalization and antagonism. J Pharmacol Exp Ther 272(1):100–111PubMedGoogle Scholar
  27. Sellors K, Jones A, Chan B (2014) Death due to intravenous use of a-pyrrolidinopentiophenone. Med J Aust 201(10):601–603CrossRefGoogle Scholar
  28. Simmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152–160CrossRefGoogle Scholar
  29. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168(2):458–470CrossRefGoogle Scholar
  30. Spiller HA, Ryan ML, Weston RG, Jansen J (2011) Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol 49(6):499–505CrossRefGoogle Scholar
  31. Sykutera M, Cychowska M, Bloch-Boguslawska E (2015) A fatal case of pentedrone and α-pyrrolidinovalerophenone poisoning. J Anal Toxicol 39(4):324–329CrossRefGoogle Scholar
  32. Vardakou I, Pistos C, Dona A, Spiliopoulou C, Athanaselis S (2012) Naphyrone: a “legal high” not legal any more. Drug Chem Toxicol 35(4):467–471CrossRefGoogle Scholar
  33. Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C (2012) Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 8(1):65–68CrossRefGoogle Scholar
  34. WHO Expert Committee on Drug Dependence (1985) Twenty-second report. In: World Health Organization technical report series, vol 729. World Health Organization, Geneva, p 8Google Scholar
  35. Zawilska JB (2014) Mephedrone and other cathinones. Curr Opin Psychiatry 27(4):256–262CrossRefGoogle Scholar
  36. Zawilska JB, Wojcieszak J (2013) Designer cathinones—an emerging class of novel recreational drugs. Forensic Sci Int 231(1–3):42–53CrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019

Authors and Affiliations

  1. 1.Controlled Substance Staff, Center for Drug Evaluation and ResearchFood and Drug AdministrationSilver SpringUSA

Personalised recommendations